THOR MEDICAL competitors & alternatives

AdvanCell Isotopes Pty LtdBiotechAustralia

73% matchAI 0/100Green 0/100

Biotech

AdvanCell Isotopes Pty Ltd is an Australian medical-isotope company developing technologies to produce isotopes used in targeted radiopharmaceutical cancer treatments. It serves radiopharmaceutical developers, pharmaceutical companies, and nuclear-medicine providers seeking reliable supplies of therapeutic isotopes.

Atley SolutionsBiotechnologySweden

66% match

Biotechnology

Atley Solutions is a global leader in commercial products and services for astatine-related (At-211) radiopharmaceutical development and scalable manufacturing, originating from research at the University of Gothenburg.

Similar pharmaceuticals company

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, focused on the development of diagnostic and therapeutic radiopharmaceuticals.

radiopharma rival LantheusBiotechnology & Pharmaceuticals

66% match

Biotechnology & Pharmaceuticals

Lantheus is a radiopharmaceutical-focused company that develops diagnostic and therapeutic products, with a focus on oncology, neurology, and cardiology. The company serves patients and healthcare providers by delivering life-changing science to improve medical outcomes.

Bwxt MedicalPharmaceuticalsCanada

64% match

Similar pharmaceuticals company

BWXT Medical Ltd. is a nuclear medicine company headquartered in Kanata, Ontario, with additional operations in Vancouver, British Columbia, providing contract manufacturing services and medical isotopes.

Similar pharmaceuticals company

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.

Pharmaceuticals, Biotechnology & Life Sciences

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.

PENTIXAPHARM HLDGPTP · PharmaceuticalsGermany

63% matchPublic

Similar pharmaceuticals company

Pentixapharm Holding AG is a clinical-stage radiopharmaceutical company that develops first-in-class radiopharmaceutical diagnostics and therapeutics, focusing on CXCR4-targeted compounds. The company serves patients and healthcare providers by advancing drug candidates through clinical trials, including Phase III-ready programs.

Shorla PharmaPharmaceuticalsIreland

62% match

Similar pharmaceuticals company

Shorla Pharma (operating as Shorla Oncology) develops and commercializes innovative oncology drugs, focusing on indications where existing treatments are limited, in shortage, or inadequate. The company provides specialized cancer treatments and accessible pharmaceutical options for patients.

Cao Pharmaceuticals Inc.15PharmaceuticalsUnited States

62% matchPrivate

Similar pharmaceuticals company

Cao Pharmaceuticals Inc. develops anti-cancer drugs utilizing natural anti-cancer compounds. The company focuses on research, product pipelines, and developing lead drug candidates for cancer treatment.

Similar pharmaceuticals company

Advanced Accelerator Applications (AAA) is a French pharmaceutical company focused on molecular nuclear medicine, developing and manufacturing radiopharmaceuticals for diagnosis and targeted cancer treatment. Its products include Lutathera and diagnostic agents such as NETSPOT, serving oncology and nuclear-medicine clinicians and patients; AAA was acquired by Novartis in 2018.

Similar pharmaceuticals company

Algeta ASA was a Norwegian biopharmaceutical company focused on developing targeted radiopharmaceutical cancer treatments. Its leading product, Xofigo (radium-223 dichloride), treated adults with castration-resistant prostate cancer with symptomatic bone metastases; Bayer acquired Algeta in 2014.